Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells
American Journal of Clinical Pathology · 2023
DOI: 10.1093/ajcp/aqac174 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Sarah J Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Boston, MA, US. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AbbVie, Stemline Therapeutics.
Abstract (Originalsprache)
Objectives
Targeted therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN) have presented a diagnostic dilemma for differentiating residual BPDCN from reactive plasmacytoid dendritic cells (pDCs) because these conditions have a similar immunoprofile, necessitating discovery of additional diagnostic markers.
Methods
Fifty cases of BPDCN involving bone marrow (26/50) and skin (24/50) as well as other hematologic malignancies (67) and nonneoplastic samples (37) were included. Slides were stained using a double-staining protocol for the following immunohistochemical marker combinations: TCF4/CD123, TCF4/CD56, SOX4/CD123, and IRF8/CD123.
Results
The nuclear marker SOX4 is expressed in neoplastic pDCs; in our cohort, SOX4/CD123 showed 100% sensitivity and 98% specificity in distinguishing BPDCN from reactive pDCs and other neoplasms. TCF4/CD56 had a 96% sensitivity and 100% specificity for BPDCN. IRF8 is a nonspecific marker that is positive in BPDCN and pDCs as well as other myeloid malignancies.
Conclusions
The novel immunohistochemical combination SOX4/CD123 distinguishes BPDCN, including CD56-negative BPDCN, from both reactive pDCs and other neoplasms. Because of their high diagnostic sensitivity and specificity, the double-staining marker combinations TCF4/CD123, TCF4/CD56, and SOX4/CD123 can be used to confirm lineage in BPDCN cases and detect minimal/measurable residual disease in tissue specimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, US.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
ORCID-Profile: Sarah J Wu
Förderung
- NCI NIH HHS
- AbbVie
- Stemline Therapeutics
- QIAGEN
- Leukemia and Lymphoma Society
- NIH
Zitieren
APA
Wu, S. J., Sadigh, S., Lane, A. A., & Pinkus, G. S. (2023). Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqac174
Vancouver
Wu SJ, Sadigh S, Lane AA, Pinkus GS. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqac174
BibTeX
@article{Wu2023,
author = {Wu, Sarah J and Sadigh, Sam and Lane, Andrew A and Pinkus, Geraldine S},
title = {Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells},
journal = {American Journal of Clinical Pathology},
year = {2023},
doi = {10.1093/ajcp/aqac174}
}
EUVIMED